Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report released on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Trading Down 25.0 %

Shares of SRNE opened at $0.02 on Friday. Sorrento Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.42. The business’s 50-day moving average is $0.02 and its 200-day moving average is $0.05.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.